Inhaled pharmaceutical products maker Vectura said trading has been in line with expectations for the period from 1 April to 21 July, lifting investor sentiment.Vectura, which reported reduced losses for the year in May, reported revenue rose 7% to £42.9m, compared to the figures last year.The company said, "With multiple short-term catalysts ahead from the clinical programmes, as well as potential licensing opportunities, Vectura looks forward to continued good progress in the second half of 2011."Vectura highlighted that its larger partner Novartis will file its drug candidate to treat chronic obstructive pulmonary disease, a respiratory disorder, by the end of 2011, with an expectation of launch in 2012 and Novartis' asthma treatment indacaterol is expected to be launched in 2013. Shares of the company surged 1.2% to 93.1p in morning trade in London.AR